The Cutaneous Lymphoma Foundation is pleased to provide the following published research abstracts and reports to provide an outlook on cutaneous lymphoma research:
In the second of our Industry Spotlight series, CLF CEO Susan Thornton caught up with Dr. Paul Rubin, Executive Vice President of miRagen Therapeutics at the recent T-Cell Forum in San Francisco. miRagen Therapeutics is a biotech company based in Boulder, Colorado that focuses on a specific cell mechanism of action called microRNA. Watch Susan's interview with Dr. Rubin video. miRagen is currently conducting a Phase I clinical trial in cutaneous lymphoma, learn more at www.clinicaltrials.gov.
CLF CEO, Susan Thornton had the chance to sit down with Dr Rick Straube, Senior VP and Chief Medical Officer of Soligenix, Inc. recently to talk about their clinical trial for treating early stage cutaneous lymphoma. The treatment process uses a new topical photosensitizing agent (synthetic hypericin) and fluorescent light. We invite you to view Susan's interview with Dr. Straube and share with us your thoughts on this new potential treatment.
Journal of the American Academy of Dermatology, February 2015, Volume 72, Issue 2, Pages 286–292, http://www.jaad.org
OncoTherapy Network, February 3, 2015, www.oncotherapynetwork.com
To read abstract:
Blood Journal, January 27, 2015, www.bloodjournal.org
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.